Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
--------
Question: Paragraph: The Idaho State Journal reports that last year there were nearly 6,600 STD cases, including HIV, up from fewer than 6,300 in 2016. Cases are also up nationally, with Centers for Disease Control and Prevention announcing last week that nearly 2.3 million cases of chlamydia, gonorrhea and syphilis were diagnosed in the United States in 2017. Kimberly Matulonis-Edgar of the Idaho Department of Health and Welfare says experts in the state and across the country are struggling to understand what's driving the increase. The most prevalent STDs reported nationally and in Idaho are gonorrhea and chlamydia. State health officials say that the rate of reported gonorrhea cases in Southeast Idaho fell about 14 percent from a year ago, but jumped more than 200 percent in south-central Idaho. ___ Information from: Idaho State Journal, http://www.journalnet.com Claim: Health experts alarmed by jump in STDs in Idaho.

Answer: A jump in reports of sexually transmitted diseases in Idaho has health experts worried.

Question: Paragraph: Researchers from the University of Glasgow reported the results in the New England Journal of Medicine on Monday. They compared the causes of death of 7,676 Scottish men who played soccer with 23,000 similar men from the general population born between 1900 and 1976. Over a median of 18 years of study, 1,180 players and 3,807 of the others died. The players had a lower risk of death from any cause until age 70. However, they had a 3.5 times higher rate of death from neurodegenerative diseases such as Alzheimer's or Parkinson's. In absolute terms, that risk remained relatively small 1.7% among former players and 0.5% for the comparison group. Former players also were more likely to be prescribed dementia medicines than the others were. The results "should not engender undue fear and panic," Dr. Robert Stern, a Boston University scientist who has studied sports-related brain trauma, wrote in a commentary published in the journal. The findings in professional players may not apply to recreational, college or amateur-level play, or to women, Stern noted. "Parents of children who headed the ball in youth or high-school soccer should not fear that their children are destined to have cognitive decline and dementia later in life. Rather, they should focus on the substantial health benefits from exercise and participation in a sport that their children enjoy," while also being aware of the risks of head-balling, Stern wrote. English Football Association chairman Greg Clark said "the whole game must recognize that this is only the start of our understanding and there are many questions that still need to be answered. It is important that the global football family now unites to find the answers and provide a greater understanding of this complex issue." The association and players' union sponsored the study. "We need to kick on now and understand what it means, because that's all an awful lot we don't know," English FA chief executive Mark Bullingham said. "We don't know if concussion was the cause or whether it was heading or whatever or whether it's the old heavy ball or something entirely different." But the association's medical advisory group has not deemed it necessary to issue to change how the game is played, even reducing heading among younger age groups. "In youth football, you might want to reduce the likelihood of aerial challenges," Bullingham said. "But our research shows this has already been reduced significantly over the years as we change to small size of pitches, move to possession-based football and now rolling substitutes." Referees across all levels can stop games for three minutes to fully assess head injuries, but some experts believe that is not long enough. The English FA also is pushing soccer's global lawmaking body for the introduction of concussion substitutes, with an additional player switch or as a temporary replacement. Campaigning to discover more about the long-term impact of head injuries in soccer has been led in England by the family of former England striker Jeff Astle, whose death at age 59 in 2002 was attributed to repeatedly heading heavy, leather balls. In 2017, a British study of brains of a small number of retired players who developed dementia highlighted the degenerative damage possibly caused by repeated blows to the head. ___ AP Chief Medical Writer Marilynn Marchione in Milwaukee contributed to this report. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content. ___ More AP soccer: https://apnews.com/Soccer and https://twitter.com/AP_Sports Claim: Study raises fresh dementia concerns from playing pro soccer.

Answer: A study of former professional soccer players in Scotland finds that they were less likely to die of common causes such as heart disease and cancer compared with the general population but more likely to die from dementia. The results raise fresh concerns about head-related risks from playing the sport at least for men at the pro level.

Question: Paragraph: A pharmacist counts pills in a pharmacy in Toronto in this January 31, 2008 file photo. Sales of prescription drugs in the United States grew by just 3.8 percent in 2007, marking the lowest growth rate since 1961, according to data compiled by IMS Health. REUTERS/Mark Blinch Total U.S. prescription drug sales reached $286.5 billion last year with slowing growth blamed on factors including patent expirations of lucrative medicines that opened the door to cheaper generic versions. Other reasons cited by IMS in its annual U.S. Pharmaceutical Market Performance Review were fewer new product approvals, safety concerns, and the leveling of year-over-year growth from the Medicare Part D program. The 3.8 percent growth rate compares to 8 percent growth seen in 2006. "The moderating growth trend that began in 2001 resumed last year following the one-time impact on market growth in 2006 from the implementation of Medicare Part D," Murray Aitken, IMS's senior vice president for healthcare insight, said in a statement. Cholesterol drugs, such as Pfizer Inc's Lipitor, once again led all therapy groups with prescription sales of $18.4 billion in 2007 despite a 15.4 percent decline in sales, primarily due to the availability of cheaper generics. Acid reflux medicines known as proton pump inhibitors, including AstraZeneca's Nexium, ranked second with prescription sales of $14.1 billion and 2.8 percent growth. Antipsychotics, such as Eli Lilly and Co's Zyprexa, overtook antidepressants as the third largest therapeutic class with $13.1 billion in sales and a 12.1 percent growth rate, according to IMS, which provides industry data on drug prescriptions and sales. Brand name drugs with some $17 billion in sales lost patent protection in 2007, helping drive prescription volume growth of 10 percent for generic medicines. Generic drugs claimed 67.3 percent of U.S. prescriptions dispensed in 2007, IMS found. IMS is forecasting compound annual U.S. pharmaceutical sales growth of 3 percent to 6 percent through 2012, noting that new biotech medicines and vaccines as well as the expected launch of a handful of drugs with at least $1 billion a year potential will partially offset major patent expirations. Some $13 billion in branded products are likely to start facing generic competition this year, IMS said. "The U.S. pharmaceutical market has entered a new era one characterized by more modest growth due to the continuing impact of new generics products, fewer and more narrowly indicated novel medications and closer scrutiny of safety issues," Aitken said. Claim: U.S. drug sales grew at slowest rate since 1961: IMS.

Answer:
Sales of prescription drugs in the United States grew by just 3.8 percent in 2007, marking the lowest growth rate since 1961, according to data compiled by IMS Health.